SQZ Biotechnologies (NYSE:SQZ) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

SQZ Biotechnologies (NYSE:SQZ – Get Rating) announced its earnings results on Thursday. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.01), Fidelity Earnings reports. SQZ Biotechnologies had a negative return on equity of 57.79% and a negative net margin of 303.43%.

SQZ Biotechnologies Stock Up 4.6 %

NYSE SQZ opened at $3.39 on Friday. The company has a market capitalization of $95.43 million, a P/E ratio of -1.28 and a beta of 2.65. SQZ Biotechnologies has a 12-month low of $2.61 and a 12-month high of $16.17. The firm has a 50-day moving average price of $3.25 and a two-hundred day moving average price of $4.31.

Analysts Set New Price Targets

Separately, Chardan Capital began coverage on shares of SQZ Biotechnologies in a report on Wednesday, May 25th. They set a “buy” rating and a $17.00 target price for the company.

Insider Buying and Selling at SQZ Biotechnologies

In other SQZ Biotechnologies news, Director Klavs F. Jensen acquired 14,326 shares of the business’s stock in a transaction on Wednesday, May 25th. The stock was purchased at an average price of $3.52 per share, with a total value of $50,427.52. Following the acquisition, the director now directly owns 353,309 shares of the company’s stock, valued at approximately $1,243,647.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 18.00% of the company’s stock.

Institutional Trading of SQZ Biotechnologies

A hedge fund recently raised its stake in SQZ Biotechnologies stock. Charles Schwab Investment Management Inc. lifted its position in shares of SQZ Biotechnologies (NYSE:SQZ – Get Rating) by 7.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,693 shares of the company’s stock after acquiring an additional 4,196 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.22% of SQZ Biotechnologies worth $292,000 as of its most recent filing with the Securities and Exchange Commission. 66.56% of the stock is currently owned by institutional investors and hedge funds.

About SQZ Biotechnologies

(Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.